Form 8-K/A - Current report: [Amend]
SEC Accession No. 0000875045-22-000023
Filing Date
2022-07-20
Accepted
2022-07-20 15:08:47
Documents
14
Period of Report
2022-07-20
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K/A biib-20220720.htm   iXBRL 8-K/A 32685
2 EX-99.1 exhibit991-q22022pressrele.htm EX-99.1 511808
6 newbiogenlogo.jpg GRAPHIC 2811
  Complete submission text file 0000875045-22-000023.txt   724979

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT biib-20220720.xsd EX-101.SCH 1921
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT biib-20220720_lab.xml EX-101.LAB 24137
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT biib-20220720_pre.xml EX-101.PRE 12524
8 EXTRACTED XBRL INSTANCE DOCUMENT biib-20220720_htm.xml XML 10561
Mailing Address 225 BINNEY STREET CAMBRIDGE MA 02142
Business Address 225 BINNEY STREET CAMBRIDGE MA 02142 7814642000
BIOGEN INC. (Filer) CIK: 0000875045 (see all company filings)

EIN.: 330112644 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 000-19311 | Film No.: 221094056
SIC: 2836 Biological Products, (No Diagnostic Substances)